Gilead Sciences, Inc.

Epitherapeutics Aps

Qasim Khan

Mukund Mehrotra

Thomas Boesen

Marc A Labelle

Farman Ullah

Ramkrishna Reddy Vakiti

Ying Yang

Neerja Saraswat

Utpal Sharma

Marc Labelle

The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form 

Inhibitors of histone demethylases

Compounds of the form In which Q is selected from &#x2014;CH&#x2550;NR, &#x2014;W, &#x2014;CHNHR, &#x2014;CH&#x2550;O and &#x2014;CH(OR)capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.

Growing community of inventors

Winnipeg, Canada

Qasim Khan